Ono Pharmaceutical (United Kingdom)

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

• Neuroscience 4.6×
• Medicine 4.2×
• Biochemistry, Genetics and Molecular Biology 2.1×

By fractional works in all years, weighted toward what it does more of than the world: Inflammation, Oxidative Stress, Cancer, Breast Cancer, Clinical Practice Guidelines, Bisphosphonates, Osteonecrosis of the Jaw and Bone Resorption.

By volume in 2022–2025: Lung Cancer Treatments and Mutations, Cancer Immunotherapy and Biomarkers, Peptidase Inhibition and Analysis and Melanoma and MAPK Pathways.

1. 1 Lung Cancer Treatments and Mutations Pulmonary and Respiratory Medicine 0 works
2. 2 Cancer Immunotherapy and Biomarkers Oncology 0 works
3. 3 Peptidase Inhibition and Analysis Oncology 0 works
4. 4 Melanoma and MAPK Pathways Molecular Biology 0 works
5. 5 Gastric Cancer Management and Outcomes Pulmonary and Respiratory Medicine 0 works
6. 6 Genetic Neurodegenerative Diseases Cellular and Molecular Neuroscience 0 works
7. 7 Parkinson's Disease Mechanisms and Treatments Neurology 0 works
8. 8 Parkinson's Disease and Spinal Disorders Neurology 0 works
9. 9 Lung Cancer Diagnosis and Treatment Pulmonary and Respiratory Medicine 0 works

Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

Output in 2018–2022 was 72% lower than in 2013–2017.

• University College London
• Imperial College London
• King's College London
• Queen Mary University of London
• London School of Economics and Political Science
• University of London
• Brunel University of London
• London School of Hygiene & Tropical Medicine